The fusion protein of respiratory syncytial virus was purified by affinity chromatography using a monoclonal antibody. Under various conditions the protein was recovered as a 145K dimer or a 70K monomer. The 70K monomer was composed of disulphide-linked fragments of 48K and 23K. Polyclonal rabbit serum produced to the dimerized fusion protein neutralized virus but did not inhibit fusion, while rabbit serum to the 2-mercaptoethanol-treated dimerized protein neutralized virus and inhibited fusion of infected cells. Only the latter serum strongly recognized the 23K fragment when studied by Western blot analysis. 0000-6298 © 1985 SGM Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11 On: Sun, 30 Dec 2018 16:40:20 410 E. E. WALSH, M. W. BRANDRISS AND J. J. SCHLESINGER METHODS Cells and virus.
INTRODUCTION
Respiratory syncytial virus (RSV), the major cause of severe lower respiratory infection in infants and young children (Kim et al., 1973) , is an enveloped RNA virus related to the paramyxoviruses (Kingsbury et al., 1978) . No useful RSV vaccine is currently available, as neither killed nor live viral vaccines have provided protection (Kim et al., 1969; Belshe et al., 1982) . Information regarding the viral proteins involved in infectivity and in interacting with" neutralizing antibody may be useful in the development of an RSV vaccine.
Between seven and ten viral proteins ranging in molecular weight from 200000 to 9000 (200K to 9K) have been described for RSV (Cash et al., 1977; Dubovi, 1982) . Two of these, a 90K and a 70K protein, are envelope glycoproteins (Peeples & Levine, 1979; Gruber & Levine, 1983) which interact with neutralizing antibodies (Walsh et al., 1984; Walsh & Hruska, 1983; . These RSV glycoproteins possess properties similar to the envelope glycoproteins of the related paramyxovirus group. Evidence has been presented suggesting that the 90K protein (GP90) initiates infectivity by mediating viral attachment to host cells, analogous to the role of the paramyxovirus haemagglutinin (Walsh et al., 1984) . Unlike the paramyxoviruses, however, haemagglutinating activity has not been described for RSV. Polyclonal antibody to GP90 neutralizes virus possibly by preventing attachment of the virus to host cells (Walsh et al., 1984) . Several investigators have demonstrated that VP70 consists of disulphide-linked fragments of approximately 50K and 20K (Fernie & Gerin, 1982; Gruber & Levine, 1983) , a structural characteristic similar to the paramyxovirus fusion proteins (Choppin & Scheid, 1980) . In addition, a monoclonal antibody directed to VP70 inhibits fusion of previously infected cells (Walsh & Hruska, 1983) , although other neutralizing monoclonal antibodies to VP70 do not inhibit fusion .
Because further characterization of the RSV fusion protein would be aided by the availability of purified VP70, we purified this protein by affinity chromatography and characterized its electrophoretic properties by polyacrylamide gel electrophoresis (PAGE). The biological activity of polyclonal antisera raised to purified VP70 was also investigated.
-70 °C until used. A second rabbit was immunized with reduced VP70, utilizing the same immunization scheme except that the VP70 was first reduced by treatment with 5% 2-ME for 1 h. The free -SH groups were not blocked by alkylation prior to immunization.
The specificity of the rabbit sera to RSV proteins was determined by Western blotting as previously described (Walsh et al., 1984) . Briefly, uninfected and RSV-infected HEp-2 cell lysates were electrophoresed on an 11% SDS polyacrylamide gel and transferred to nitrocellulose paper. The paper was developed by incubation in a 1:200 dilution of immune rabbit serum followed by ~ 251-1abelled staphylococcal Protein A (IPA, New England Nuclear) and autoradiography. Preimmune rabbit serum, rabbit antiserum to GP90 and a mouse monoclonal antibody to the RSV nucleocapsid protein (NP44) were used as controls.
Virus neutralization was assayed by a standard 60~o plaque reduction neutralization test using heat-inactivated immune rabbit sera. The ability of the rabbit sera to inhibit fusion of previously infected cells was tested as previously described (Walsh & Hruska, 1983) . HEp-2 cell monolayers, grown on glass coverslips, were infected with 103 p.f.u, of RSV and incubated in MEM for 8 h. The medium was then aspirated and replaced with MEM containing various dilutions of heat-inactivated immune rabbit serum to VPT0. Individual coverslips were removed after 2, 3 and 4 days, washed with PBS, fixed in cold acetone and RSV-infected cells identified by indirect immunofluorescence using a monoclonal antibody to RSV nucleocapsid protein and FITC-conjugated goat antimouse antibody. Controls for the assay measuring inhibition of fusion were performed using a fusion-inhibiting monoclonal antibody to VP70, preimmune rabbit serum and a neutralizing polyclonal rabbit antiserum to GP90.
RESULTS
Approximately 2 mg of protein was purified from fifty 32 oz bottles of RSV-infected HEp-2 cells. Analysis of the isolated protein by PAGE under non-reducing conditions after treatment with 0.1 ~o SDS or 2~o SDS at room temperature demonstrated a single major band of 145K ( Fig.  1 ). However, treatment of the purified protein with SDS and heat to 100 °C revealed a single 70K band (Fig. 1, lane 2) with complete loss of the 145K protein. Similarly, treatment of the protein with SDS, 5~0 2-ME and heating to 100 °C resulted in the appearance of two new bands, 48K and 23K, and the complete disappearance of the 145K and 70K bands (Fig. 1, lane 3) . Only partial conversion of the 145K protein to 70K or 48K and 23K bands was seen when the samples were heated to 56 °C in non-reducing or reducing buffer respectively (not shown). PAGE (1978) .
analysis of the purified protein treated with 2~o SDS and 5~ 2-ME at room temperature revealed only faint bands at 48K and 23K in addition to a heavy 145K band. The a m i n o acid analysis of the purified protein with comparison to the a m i n o acid content of the Sendai virus fusion protein is shown in Table 1 . The proteins are quite similar in a m i n o acid content and are characterized by low methionine content. The specificity of the two rabbit hyperimmune antisera determined by Western blotting is shown in Fig. 2. A major difference was noted in the RSV protein specificity of the two rabbit antisera. The rabbit antiserum made to the 2-ME untreated dimer of VP70 reacted with a 145K protein when RSV-infected cell lysates were prepared for electrophoresis at room temperature in non-reducing buffer containing 0.1% SDS (Fig. 2, lane 8) . The same serum reacted with a 70K proteinwhen the RSV-infected cell lysates were prepared by heating to 100 °C in non-reducing buffer containing 2% SDS (Fig. 2, lane 3) . When the RSV-infected cell lysate was prepared by boiling in 2% SDS and 5~ 2-ME, the serum reacted mainly with a 48K protein (Fig. 2, lane 5) . In contrast, the rabbit antiserum produced by immunization with reduced VP70 reacted strongly with both the 23K and 48K protein when the RSV-infected cell lysate was prepared by boiling in 2~ SDS and 5% 2-ME (Fig. 2, lane 6) . This serum also reacted with the 145K and 70K proteins similar to the pattern described above (Fig. 2, lanes 4, 7) . There was no reactivity to HEp-2 cell proteins with either sera (Fig. 2, lane 2) .
The hyperimmune rabbit serum to both reduced and non-reduced VP70 neutralized RSV to a titre of 1:640. However, only the antiserum to reduced VP70 was capable of inhibiting fusion of previously infected HEp-2 cells. Incubation of infected HEp-2 cells with preimmune serum resulted in the progressive development of both large syncytia and new foci of infection over the 4 days of the experiment (Fig. 3a and 4a) . Infected cells incubated with rabbit antiserum to reduced VP70 showed only single infected cells by day 2 and progression to syncytia was not seen even at day 4 ( Fig. 3 b and 4 b) . However, incubation of infected cells with the rabbit antiserum to non-reduced VP70 did not inhibit fusion, and progression to syncytia occurred (Fig. 3c ). Since the infected ceils were incubated in a neutralizing dilution of rabbit serum (1 : 100), no new foci of infection developed over the 4 day period. Similarly, when the infected cells were incubated with a neutralizing concentration of rabbit antiserum to GP90, syncytia developed, but no newly infected foci of cells were seen (Fig. 3d ).
DISCUSSION
A major obstacle in the study and characterization of the RSV proteins has been the inability to obtain sufficient quantities of purified virus free of contaminating host cell proteins. We have previously reported the purification of the major RSV glycoprotein, GP90, by affinity chromatography using a monoclonal antibody, and characterized its role in viral infectivity (Walsh et al., 1984) . In this paper we describe the purification of the other RSV envelope glycoprotein, VP70, utilizing similar techniques. It is apparent that large quantities of the RSV fusion protein are synthesized by infected HEp-2 cells, thus allowing the purification of several milligrams of protein. It is unlikely that this quantity of purified protein would be available from purified virus, since RSV does not grow to high titre.
Certain characteristics of VP70 are of interest. In the non-reduced state at room temperature VP70 appears to exist as a dimer of 145K. This dimerized form was seen in both the purified protein by PAGE and in RSV-infected cell lysates by Western blot analysis. Conversion from the 145K dimer to a 70K monomer by treatment with SDS and heat suggests that the dimer is linked by non-covalent forces rather than by disulphide bonds. The presence of VP70 as a dimer was unexpected since the described paramyxovirus fusion proteins exist as monomers, while the haemagglutinin of paramyxoviruses is a disulphide-linked dimer (Gething et al., 1978) . We have previously presented evidence suggesting that the large RSV glycoprotein, GP90, is analogous to the paramyxovirus haemagglutinin, but did not identify disulphide-linked dimers of GP90 under various conditions (Walsh et al., 1984) .
The reduction of VP70 with 2-ME to 48K and 23K fragments, which is characteristic of paramyxovirus fusion proteins as well, and the ability of hyperimmune rabbit serum to 2-MEtreated VP70 to inhibit fusion of previously infected cells confirms that VP70 is the RSV fusion protein (Fo). Similar to the paramyxoviruses, the RSV fusion protein, F0, is probably cleaved to the disulphide-linked fragments 48K (F~) and 23K (F2) by cellular enzymes, thus yielding the active fusion protein (F1,2) (Hsu et al., 1981) . The amino acid content of the RSV fusion protein is strikingly similar to that of the Sendai virus fusion protein, both being characterized by a low methionine content (Gething et al., 1978) . This accounts for the difficulty in labelling F 0 with [35S]methionine.
The rabbit antisera made to the purified VP70 had interesting characteristics. The antiserum made to the dimer of VP70, although able to neutralize virus, did not inhibit fusion of infected cells. In contrast, the rabbit antiserum made to the 2-ME-reduced dimer of VP70 neutralized virus and inhibited fusion. This suggests that only the latter antiserum binds to the fusion epitope of VP70 in vitro. Analysis of these two antisera by Western blotting did suggest qualitative differences in their reactivity. The antiserum made to the 2-ME-reduced dimer of VP70 demonstrated strong reactivity against both the 48K and 23K fragments of VP70, whereas the antiserum made to the untreated dimer of VP70 clearly bound to the 48K fragment but only questionably reacted to the 23K fragment. Although the differences in biological activity and protein reactivity of these two antisera may be due to variations in immune response of the immunized rabbits and not the form of the immunogen, the findings may, nevertheless, have relevance to future use of purified RSV proteins as a vaccine. Merz has suggested that an effective paramyxovirus vaccine should induce both neutralizing and fusion-inhibiting antibody since the prevention of cell--cell fusion may be important in containment of paramyxovirus infection (Merz et al., 1981) . It has been suggested that the atypical measles syndrome which occurred following vaccination with inactivated measles virus, and perhaps the adverse response to formalin-inactivated RSV vaccine, were related to the induction of biologically inactive antibody to the fusiFon protein (Choppin & Scheid, 1980) . Use of purified RSV fusion protein as a vaccine will require careful assessment of the biological activity of the induced antibodies, since it appears from the data presented that neutralizing fusion-inhibiting antibody is not necessarily induced by immunization with the native dimerized form of VP70.
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